Exelixis (EXEL:NSD) was recently downgraded from a “buy” rating to a “hold” rating in a research report issued to clients and investors. Although two analysts have rated the EXEL stock with a hold rating, eight have issued a buy rating, and the consensus rating of the EXEL stock is “Strong Buy” with an average price target of $25.06, according to Stock Target Advisor.
EXEL Stock Price Analysis:
The business has a 50-day moving average price of $17.76 and a 200-day moving average price of $16.87. EXEL has a one-year low of $14.87 and a one-year high of $23.29, and the company has a market cap of $6.45 billion, a P/E ratio of 34.90, a P/E/G ratio of 0.80, and a beta of 0.68.
Quarterly Earnings Review:
The biotechnology company last posted its quarterly earnings data on Tuesday, February 7th, reporting ($0.09) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.04). The firm had revenue of $423.92 million during the quarter, compared to analyst estimates of $418.71 million, and had a net margin of 11.31% and a return on equity of 7.54%.
During the same period in the prior year, the company posted $0.29 earnings per share, and its revenue for the quarter was down 6.0% compared to the same quarter last year. As a group, sell-side analysts predict that Exelixis will post $0.66 EPS for the current fiscal year.
Insider Transactions:
There have been recent insider transactions at Exelixis, including EVP Jeffrey Hessekiel selling 38,930 shares of the EXEl stock in a transaction on Wednesday, April 5th, for a total value of $778,989.30. Following the sale, the executive vice president now owns 582,435 shares of the company’s stock, valued at $11,654,524.35.
Institutional investors and hedge funds have also recently made changes to their positions in EXEL. Overall, insiders own 2.90% of the EXEL stock.
EXEL Stock-Analyst Ratings:
Despite the recent downgrade, Exelixis has a number of positive ratings from analysts, and the EXEL stock has a Strong buy rating with a high target price. While the company’s recent earnings report was below expectations, there have been insider transactions and institutional investments in the company.
Company Profile:
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
